NFX.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 04:44):
Our systems believe the stock currently is undervalued by 0.19% compare to its pairs and should correct upwards.

Stats
Today's Volume	592 174
Average Volume	2.30M
Market Cap	1.32M
EPS	£-0.000300 ( Q4 \| 2024-03-31 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	£0 (0.00%)

AMYT.L -11.73%

APH.L -0.35%

AVCT.L -1.10%

AZN.L -0.47%

BMK.L 2.34%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -0.80%

DPH.L 0.05%

EAH.L 3.20%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 3.33%

GNS.L 1.44%

GSK.L -0.56%

HCM.L -0.36%

HEMO.L -2.90%

HIK.L -0.58%

IMM.L 4.81%

INDV.L -0.32%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -6.67%

OXB.L 1.69%

PRM.L -4.82%

PRTC.L -0.23%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 9.44%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 4.05%

STX.L 2.70%

TILS.L 8.33%

TRX.L -2.06%

VAL.L 0.00%

VEC.L 0.00%

Correlation (AI algo v.1.1b): Undervalued: 0.19% £0.162 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Nuformix PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nuformix PLC Financials

Annual	2023
Revenue:	£0
Gross Profit:	£-36 749.00 (0.00 %)
EPS:	£-0.000800

FY	2023
Revenue:	£0
Gross Profit:	£-36 749.00 (0.00 %)
EPS:	£-0.000800

FY	2022
Revenue:	£0
Gross Profit:	£0 (0.00 %)
EPS:	£-0.00130

FY	2022
Revenue:	£50 000.00
Gross Profit:	£48 305.00 (96.61 %)
EPS:	£-0.00190

Financial Reports:

No articles found.

Nuformix PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nuformix PLC

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.